25th Feb 2022 09:40
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Instructs Citigroup Global Markets Ltd, part of Citigroup Inc, to conduct the USD150 million first tranche of the USD300 million share buyback that it announced on Thursday. The initial phase will begin on Friday and end by June 25. Hikma had announced the buyback programme with its annual results, saying it reflected its strong cash generation, balance sheet strength, and confidence in future growth prospects. Hikma also had declared a final dividend of 36 cents, a 5.9% boost from a shareholder payout of 34 cents the year before. Its full-year dividend amounted to 54 US cents, up 8.0% from 50 cents.
Current stock price: 1,897.50 pence, up 3.5% on Friday
12-month change: down 19%
By Tom Waite; [email protected]
Copyright 2022 Alliance News Limited. All Rights Reserved.
Related Shares:
Hikma Pharmaceuticals